Discussion

In previous sections, we have reviewed evidence supporting that nanomedicine is not only an academic trend or a future promise. Instead, it is a validated and increasingly diversified drug delivery strategy. Evidence shows that it not only impacts therapeutic availability but has also impacted the technological and economic landscape of the pharmaceutical industry.

From a historical perspective, early nanotechnology-based medicines entered the market before widely cited milestones; however, certain approvals became emblematic as they consolidated a broader translational narrative. Doxil®, for example, was not merely a liposomal formulation but a clinical proof that nanocarriers could meaningfully reshape pharmacokinetics, tolerability, and therapeutic utility, helping to legitimize nanomedicine as a viable development strategy [166]. This probably explains the predominance of Doxil® when citing nanotechnology milestones. More recently, the clinical success of nucleic-acid delivery platforms further strengthened this paradigm by demonstrating that nanocarriers can enable therapeutic alternatives that are otherwise impractical due to instability, biodistribution constraints, or intracellular delivery barriers [207,208].

The diversity of platforms employed as well as their temporal evolution indicates that no single nanocarrier is universally optimal across time, therapeutic applications or technological context. Different types of nanocarriers adapt to different conditions: payload class, route of administration, target tissue accessibility, dosing frequency, and safety margins. These carriers differ in stability, formulation complexity, and susceptibility to variations in biological performance. Therefore, this evidence suggests that while translation is reachable for different types of platforms, their progression favours fit-for-purpose designs that integrate clinical demands with feasibility considerations, rather than the most sophisticated (or simplified), or fashionable vehicles. In other words, this suggests that no universal nanocarrier fits all biomedical applications, and the evolution of the field depends on several platforms demonstrating their individual potential.

Despite market growth and increasing regulatory acceptance, the costs associated with most nanotechnology-based medicines remain an important barrier to access, potentially limiting both development capacity and patient availability. This challenge is particularly evident in advanced therapies, such as gene-silencing and gene-editing treatments. However, it is important to analyse whether the high costs associated with some of these therapies reflect the intrinsic development or manufacturing expenses, or whether they are primarily driven by niche pricing related to rare diseases, small patient populations, and other pharmacoeconomic considerations, regardless of whether the therapies are advanced or conventional [209-211].

Although detailed manufacturing methods fall outside the scope of this review, manufacturability remains one of the most decisive filters for clinical advancement. The production method strongly influences the nanoparticles attributes that are critical to their biological behaviour, but also the scalability, batch-to-batch reproducibility, scalability, and directly the cost of production. Therefore, the reader is encouraged to consult the available literature on the technological constraints and advances in nanotechnology manufacturing.

The analysis of the existing challenges suggests that translation might be facilitated by the synergistic convergence of scientific, technological, regulatory, and economic actors. In this context, progress in each field must be integrated. Translation depends on rational, disease- and patient-centred designs, and also on evaluation and regulation frameworks aligned with the clinical and industrial context. The most meaningful advances will arise from cross-disciplinary integration, where advances at the nanoscale will continue growing and maturing into more and more clinically translated therapies.

Despite these constraints, the number of marketed nanomedicine products serves as both validation and inspiration for continued development. Their successful clinical translation demonstrates that during the last decades, nanomedicine has driven a paradigm shift in pharmaceutical research and development, transforming early promises into industrially mature and clinically impactful applications.